ArticleBreast cancer research and treatment2014

Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.

Vakaramoko Diaby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.